Exelixis | EXEL - Market Capitalization


Exelixis reported $12.32B in Market Capitalization this February of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.6B 10M Sep/2025
Agios Pharmaceuticals USD 2.33B 402M Sep/2025
Amgen USD 185.28B 33.35B Feb/2026
AstraZeneca USD 233.07B 17.56B Sep/2025
Bayer EUR 27.23B 2.14B Sep/2025
BioMarin Pharmaceutical USD 10.4B 142M Sep/2025
Bristol-Myers Squibb USD 91.8B 2.4B Sep/2025
Cytokinetics USD 6.58B 2.63B Sep/2025
Eisai JPY 1.45T 280.95B Sep/2025
Eli Lilly USD 722.15B 16.64B Sep/2025
Exelixis USD 10.79B 1.79B Sep/2025
Genmab DKK 80.88B 7.82B Jun/2025
Glaxosmithkline GBP 106.96B 20.08B Feb/2026
Incyte USD 16.56B 3.38B Sep/2025
Ionis Pharmaceuticals USD 10.43B 4.14B Sep/2025
MacroGenics USD 114M 8M Feb/2026
Merck USD 294.09B 84.45B Feb/2026
Moderna USD 10.09B 581M Sep/2025
Neurocrine Biosciences USD 13.92B 1.48B Sep/2025
Novartis USD 265.66B 9.48B Sep/2025
Pfizer USD 145.87B 10.78B Feb/2026
Sanofi EUR 118.94B 1.6B Feb/2026
Takeda JPY 7.64T 774.9B Dec/2025
Ultragenyx Pharmaceutical USD 2.9B 539M Sep/2025
Xencor USD 837M 278M Sep/2025